KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) Equity Ratio (2016 - 2026)

Supernus Pharmaceuticals has reported Equity Ratio over the past 15 years, most recently at 0.73 for Q4 2025.

  • Quarterly Equity Ratio fell 3.46% to 0.73 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.73 through Dec 2025, down 3.46% year-over-year, with the annual reading at 0.73 for FY2025, 3.46% down from the prior year.
  • Equity Ratio was 0.73 for Q4 2025 at Supernus Pharmaceuticals, down from 0.74 in the prior quarter.
  • Over five years, Equity Ratio peaked at 0.77 in Q2 2025 and troughed at 0.48 in Q4 2021.
  • The 5-year median for Equity Ratio is 0.71 (2023), against an average of 0.63.
  • Year-over-year, Equity Ratio surged 43.3% in 2023 and then decreased 3.46% in 2025.
  • A 5-year view of Equity Ratio shows it stood at 0.48 in 2021, then rose by 7.77% to 0.52 in 2022, then surged by 38.56% to 0.72 in 2023, then rose by 4.97% to 0.76 in 2024, then dropped by 3.46% to 0.73 in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Equity Ratio are 0.73 (Q4 2025), 0.74 (Q3 2025), and 0.77 (Q2 2025).